CLINICAL PRACTICE GUIDELINE GI-003 version 7 METASTATIC COLORECTAL CANCER Effective Date: March, 2014

First Page		Document Content
Date: 2014-03-28 17:58:19 Chemotherapy regimens Prodrugs Organofluorides Bevacizumab Cetuximab FOLFOX FOLFIRI Capecitabine Oxaliplatin Medicine Chemistry Pharmacology		CLINICAL PRACTICE GUIDELINE GI-003 version 7 METASTATIC COLORECTAL CANCER Effective Date: March, 2014 Add to Reading List Source URL: www.albertahealthservices.ca Download Document from Source Website File Size: 205,65 KB Share Document on Facebook

	References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC DocID: 1qSc2 - View Document
	ICECREAM: Cetuximab antibody treatment for colorectal cancer with a G13D gene mutation The ICECREAM trial has helped researchers answer an important health question. It has provided evidence that cetuximab alone is not a DocID: 1pJVg - View Document
	Translating Genomes \| Personalizing Medicine rAAV human gene editing, isogenic human disease models, phenotypic cellbased assays for precision functional genomics and targeted drug discovery  400 peer reviewed publica DocID: 1pH8J - View Document
	PAN01 biomarker poster ESMO 15.pdf DocID: 1pBTA - View Document
	ATTAX3: Panitumumab added to docetaxel, cisplatin, fluoropyrimidine in oesophagogastric cancer The ATTAX3 trial has helped researchers answer an important health question. It has provided evidence on the value of a new c DocID: 1p6wp - View Document